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Abstract
Background: TRIM5α is a restriction factor that interferes with retroviral infections in a species-
specific manner in primate cells. Although TRIM5α is constitutively expressed, its expression has
been shown to be up-regulated by type I interferon (IFN). Among primates, a particular case exists
in owl monkey cells, which express a fusion protein between TRIM5 and cyclophilin A, TRIMCyp,
specifically interfering with HIV-1 infection. No studies have been conducted so far concerning the
possible induction of TRIMCyp by IFN. We investigated the consequences of IFN treatment on
retroviral restriction in diverse primate cells and evaluated the implication of TRIM5α or TRIMCyp
in IFN-induced anti-retroviral activities.
Results: First, we show that human type I IFN can enhance TRIM5α expression in human, African
green monkey and macaque cells, as well as TRIMCyp expression in owl monkey cells. In TRIM5α-
expressing primate cell lines, type I IFN has little or no effect on HIV-1 infection, whereas it
potentates restriction activity against N-MLV in human and African green monkey cells. In contrast,
type I IFN treatment of owl monkey cells induces a great enhancement of HIV-1 restriction, as well
as a strain-tropism independent restriction of MLV. We were able to demonstrate that TRIM5α is
the main mediator of the IFN-induced activity against N-MLV in human and African green monkey
cells, whereas TRIMCyp mediates the IFN-induced HIV-1 restriction enhancement in owl monkey
cells. In contrast, the type I IFN-induced anti-MLV restriction in owl monkey cells is independent
of TRIMCyp expression.
Conclusion: Together, our observations indicate that both TRIM5α and TRIMCyp are implicated
in IFN-induced anti-retroviral response in primate cells. Furthermore, we found that type I IFN also
induces a TRIMCyp-independent restriction activity specific to MLV in owl monkey cells.
Published: 9 July 2008
Retrovirology 2008, 5:59 doi:10.1186/1742-4690-5-59
Received: 29 April 2008
Accepted: 9 July 2008
This article is available from: http://www.retrovirology.com/content/5/1/59
© 2008 Carthagena et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Retrovirology 2008, 5:59 http://www.retrovirology.com/content/5/1/59
Page 2 of 15
(page number not for citation purposes)
Background
In response to infections, eukaryotes have evolved a wide
variety of defense mechanisms. In addition to classical
innate and adaptive immunities, a third mode of immu-
nity specific to retroviral infections has recently been iden-
tified and termed "intrinsic immunity" [1]. So far, two
classes of cellular proteins that specifically interfere with
retroviral infections at the cellular level have been identi-
fied. The first class of factors is constituted of cytidine
deaminases such as APOBEC3G, which induce lethal
hypermutation of retroviral genomes (reviewed in [2,3]).
The second class of retroviral restriction factors targets
capsid proteins of incoming virions and comprises the
murine Fv1 and the primate TRIM5α proteins (reviewed
in [2,3]).
TRIM5α is responsible for a species-specific post-entry
restriction of diverse retroviruses in primate cells [4-8].
TRIM5α is a member of the large family of tripartite motif
proteins (TRIM), which is composed of proteins contain-
ing a conserved tripartite organization (known as RBCC,
for RING, B-BOX, and coiled-coil domains), followed by
a C-terminal portion of variable nature (for review, see
[9,10]). TRIM5α contains a B30.2/SPRY domain in its C-
terminus (Figure 1A), which determines the virus-specific
restriction activity of TRIM5α protein from different spe-
cies [11,12].
TRIM5α protein from Old World monkeys blocks both
human immunodeficiency virus type 1 (HIV-1) and N-
tropic murine leukemia virus (N-MLV), whereas human
TRIM5α only interferes with N-MLV infection. Most
TRIM5α variants from New World monkeys restrict sim-
ian immunodeficiency virus (SIVmac) but not HIV-1
infection [13], with the notable exception of owl monkey
(Aotus trivigartus) cells which block HIV-1 but not SIVmac
or N-MLV infections. Instead of TRIM5α, owl monkeys
express a TRIMCyp fusion protein, generated by retro-
transposition of a cyclophilin A (CypA) mRNA within the
TRIM5 locus [14,15]. This retrotransposition event led to
the expression of a chimeric protein that consists of the
RBCC motif of TRIM5 fused to a carboxy-terminal CypA
moiety [14,15] (Figure 1A). CypA is a ubiquitously
expressed and highly conserved peptidyl prolyl isomerase
that can catalyze cis/trans-isomerization of prolyl peptide
bonds. This cellular protein has been shown to bind the
HIV-1 capsid protein (CA) through a direct interaction
between the active site of CypA and an exposed loop
within the CA protein, known as the CypA binding loop
[16,17]. Capsid proteins from other retroviruses also
interact with CypA, such as feline immunodeficiency virus
(FIV), SIVcpz or SIVagm, whereas others such as MLV or
SIVmac, do not [18,19]. CypA-CA interaction can be dis-
rupted by cyclosporine A (CsA), an immunosuppressive
drug that competitively binds to the CypA active site
[17,20]. In consequence, since owl monkey TRIMCyp
proteins bind CA proteins of incoming retroviruses
through their C-terminal CypA domain, restriction can be
relieved by CsA treatment [14,15,21,22].
Like many other members of its protein family [23,24],
TRIM5α expression has been recently found to be up-reg-
ulated by type I interferon (IFN) in human cells, through
an IFN-stimulated response element (ISRE) within its pro-
moter [25]. This finding suggested that IFN might influ-
ence the retroviral activity of TRIM5α. In the particular
case of owl monkey cells, it is not known whether TRIM-
Cyp expression is also enhanced by IFN. We thus tried to
determine whether the retroviral restriction profile of dif-
ferent primate cells can be modulated by type I (α, β) and
type II (γ) IFNs, and to evaluate the role of TRIM5α and
TRIMCyp in IFN-induced anti-retroviral responses.
Methods
Cells and viruses
Cell lines of human (Homo sapiens, HeLa cells), African
green monkey (Cercopithecus aethiops, Vero cells), rhesus
macaque (Macaca mulatta, CMMT cells), and owl monkey
(Aotus trivigartus, OMK cells) origin were maintained in
Dulbecco's modified Eagle's medium containing 10%
fetal bovine serum and antibiotics.
Vesicular stomatitis virus glycoprotein (VSV-G)-pseudo-
typed retroviral vectors were generated by co-transfecting
10-cm plates of 293T cells with 10 μg of pVSV-G, 10 μg of
Gag-Pol expression plasmid and 10 μg of green fluores-
cent protein (GFP)-expressing retroviral vector, using the
ProFection calcium phosphate kit (Promega). MLV vec-
tors were made with pCFG2-eYFP and pHIT60 (Mo-MLV,
a NB-tropic strain), pCIG3N (N-tropic MLV), or pCIG3B
(B-tropic MLV). HIV-1 vectors were prepared with pCSGW
(GFP vector) and p8.91 (HIV-1 Gag-Pol). All MLV- and
HIV-derived plasmids were kindly provided by J.P. Stoye
(National Institute for Medical Research, London, UK).
SIVmac vectors were generated with pAd-SIV3+ and GAE-
CMV-GFP, which were kindly provided by F.L. Cosset
(ENS Lyon, France). The HIV SCA Gag-Pol plasmid was a
generous gift from J. Sodroski (Dana Farber Cancer Insti-
tute, Boston, MA, USA) and was co-transfected with
pCSGW, pVSV-G and pRev (10:10:8:2 ratio) to produce
HIV-1 SCA viral particles. All viral stocks were titrated on
Mus dunni tail fibroblast (MDTF) cells and analyzed by
FACS. The multiplicity of infection (MOI) is defined as
MOI = -2 ln(1-fp), where fp is the fraction of GFP-positive
MDTF cells. HeLa, Vero, CMMT or OMK cells were then
transduced with increasing doses of GFP-encoding retro-
viral vectors and the percentage of transduced GFP-posi-
tive cells was determined by FACS 48 h post-transduction
[7,8].Retrovirology 2008, 5:59 http://www.retrovirology.com/content/5/1/59
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Up-regulation of TRIM5 expression in primate cells Figure 1
Up-regulation of TRIM5 expression in primate cells. A. Schematic representation of the domain structure of TRIM5α 
and TRIMCyp proteins. C.C.: Coiled-Coil. B. Comparison of TRIM5α or TRIMCyp constitutive expression in HeLa, CMMT, 
Vero and OMK cells by quantitative RT-PCR. C. MDTF, HeLa, CMMT, Vero or OMK cells were stimulated with universal type 
I IFN (U), IFN-α, β or γ for 20 min or left untreated (-) and assessed for phosphorylated Stat1 (Tyr 701) and actin by western 
blot. D. Total RNA was extracted after 8 h of treatment with IFN-α, β or γ. TRIM5α (in HeLa, CMMT and Vero cells) or 
TRIMCyp (in OMK cells) mRNA expression levels were measured by quantitative RT-PCR and normalized to GAPDH mRNA. 
Results are expressed as fold increase, defined as the ratio of TRIM5 expression in IFN treated/untreated cells. Error bars 
reflect the SD of duplicate values in a representative experiment.
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Drug and interferon treatment
Cyclosporin A (CsA, Sigma) was prepared at 1 mM in eth-
anol and diluted further in culture medium before use.
For all experiments, IFN-α, IFN-β or IFN-γ were used at
1000 units/ml (U/ml). Human recombinants IFN-α2 is
from Schering-Plough, IFN-β is from Cytotech SA and
IFN-γ is from Roussel Uclaf. For treating MDTF cells, we
used universal type I IFN (PBL Biomedical Laboratories)
at 200 U/ml, which was found to be active on most mam-
malian cells.
Quantitative RT-PCR
Total RNA was extracted using RNeasy Mini Kit (Qiagen)
and cDNA were prepared using a Oligo(dT) primer and
SuperScript III Reverse Transcriptase (Invitrogen). Quanti-
tative PCR were performed in duplicates using 1 μl of
cDNA on a Roche LightCycler, using the LightCycler Fast
Start DNA Master SYBR Green 1 kit (Roche). Primers were
synthesized by Eurogentec. TRIM5α: TTGGATCCT-
GGGGGTATGTGCTGG (forward) and TGATATTGAAGA
ATGAGACAGTGCAAG (reverse). GAPDH: GGGAAACT-
GTGGCGTGAT (forward) and GGAGGAGTGGGTGTCGC
TGTT (reverse). CypA: AGTGGTTGGATGGCAAGC (for-
ward) and GATTCTAGGATACTGCGAGCAAA (reverse).
TRIMCyp: CAGAAGTCCAACGCTACTGGG (forward) and
CTTGCCACCAGTGCCATTATGG (reverse). PCR reactions
were carried out with a denaturation step of 10 min at
95°C followed by forty-five cycles of 10 s at 95°C, 5 s at
annealing temperature (55°C for cyclophilin A, 60°C for
TRIM5α, TRIMCyp and GAPDH) and 20 s amplification
at 72°C. Quantifications of cDNAs were determined in
reference to a standard curve prepared by amplification of
serial dilutions of PCR product or plasmids containing
matching sequences. Analyses were performed using the
second-derivative-maximum method provided by the
LightCycler quantification software, version 3.5 (Roche
Diagnostics).
Western blot analysis
Cells untreated or treated with IFN-α, β or γ at 1000 U/ml
(or with 200 U/ml of universal type I IFN in the case of
MDTF cells) for 20 min were lysed with lysis buffer (20
mM Tris HCl pH7.5, 400 mM NaCl, 1% Triton, 1 mM
EDTA, 50 mM KCl and 5 mM β-Mercaptoethanol). Cells
extracts (100 μg) were resolved by sodium dodecyl sul-
phate polyacrylamide gel electrophoresis (SDS-PAGE)
and western blotted using anti-phosphorylated Stat1 (Tyr
701) rabbit antibodies (Santa Cruz Biotechnology, Inc.)
or an anti-actin mouse mAb (Calbiochem).
siRNA
Down-regulation of TRIM5α or TRIMCyp expression by
siRNA was performed by transfecting cells with siRNA oli-
gos (Dharmacon) using HiPerFect Transfection Reagent
(Qiagen) according to manufacturer's instructions. siR-
NAs targeting human TRIM5α were H1 (GGUCAUU-
UGCUGGCUUUGU) and HA2
(GCACUGUCUCAUUCUUCAA). For African green mon-
key (agm) TRIM5α silencing, we used HA2 and A3
(GCCUUACGAAGUCUGAAAC). In order to silence
TRIMCyp expression in OMK cells, we used a siRNA tar-
geting CypA (CypA: GGGUUCCUGCUUUCACAGA).
Control siRNA transfections were performed using a luci-
ferase control siRNA (Dharmacon).
Quantification of reverse transcripts
OMK cells untreated or treated with 1000 U/ml of IFN-β
were transduced 24 h later with GFP-expressing retroviral
vectors pre-treated with DNase (Roche DNase I RNase-
free 200 U/ml, 10 mM MgCl2, 1 h at room temperature)
and harvested 6 h later. Total DNA was extracted using
DNeasy Mini Kit (Qiagen) and quantified by measuring
OD at 260 nm. Reverse transcripts were detected by PCR
on 100 ng of total DNA using primers to GFP: TACG-
GCAAGCTGACCCTGAAG (forward) and ACGAACTC-
CAGCAGGACCATG (reverse).
Results
Up-regulation of TRIM5α and TRIMCyp expression by 
IFNs in primate cells
To investigate whether type I and type II IFNs can enhance
TRIM5 (TRIM5α or TRIMCyp) expression in various pri-
mate cells, we decided to compare cell lines of human
(HeLa), African green monkey (Vero), rhesus macaque
(CMMT) and owl monkey (OMK) origin.
First, we compared the constitutive expression of TRIM5α
(HeLa, Vero and CMMT cells) or TRIMCyp (OMK cells)
transcripts in the different cell lines by quantitative RT-
PCR (Figure 1B). We found that OMK cells contain
approximately 1.5 × 107 copies/μg total RNA of TRIMCyp
transcripts, whereas HeLa and Vero cells contain 3 × 107
transcripts encoding TRIM5α. Among the four cell lines
tested, CMMT cells express the highest number of TRIM5
transcripts, with a concentration of 9 × 107 copies of
TRIM5α per μg of total RNA.
In order to verify if non-human primate cells are respon-
sive to human IFN treatment, we looked at Stat1 phos-
phorylation, which is an early post-receptor signaling
element of both type I and type II IFN pathways, and can
thus serve as a positive-indicator of IFN signaling [26]. For
this purpose, CMMT, Vero and OMK cells were treated
with 1000 U/ml of human IFN-α, β or γ for 20 min and
the activation of Stat1 was estimated by western blotting
using anti-phosphorylated Stat1 antibodies. As shown in
Figure 1C, although the different cell lines do not equally
respond to the three IFNs, both human type I (α, β) and
II (γ) IFNs can induce Stat1 phosphorylation in non-
human primate cells as well as in human cells (HeLaRetrovirology 2008, 5:59 http://www.retrovirology.com/content/5/1/59
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cells). As a control, the same assay was performed on
MDTF cells treated with 200 U/ml of universal type I IFN
(Fig 1C), which is active on most mammalian cells. MDTF
cells are devoid of any post-entry retroviral restricting
activity, since they are Fv1-null [27,28], do not encode a
TRIM5 ortholog, like all other mouse cells (reviewed in
[29]), and were found to express an inactive APOBEC3G
protein[30].
Next, we stimulated the primate cell lines with 1000 U/ml
of IFN-α, β or γ for 8 h and determined TRIM5α or TRIM-
Cyp mRNA amounts by quantitative RT-PCR. Results were
normalized to GAPDH mRNA levels. Figure 1D shows the
ratio of TRIM5α or TRIMCyp expression in IFN treated/
untreated cell, which is referred to as "Fold increase". We
found that type I IFN enhances TRIM5α mRNA expression
with induction folds ranging from 3.5 (CMMT) to 7.6
(HeLa) for IFN-α, and from 2.8 (CMMT) to 8.8 (HeLa) for
IFN-β. In contrast, IFN-γ treatment does not significantly
affect TRIM5α expression in any cell line, with fold induc-
tion values ranging from 1.4 (Vero) to 1.9 (CMMT). These
results are consistent with previous observations made in
human cells [25]. In OMK cells, stimulation by type I IFN
leads to a 4.4 (IFN-α) to 6.6 (IFN-β) fold increase of
TRIMCyp mRNA expression, whereas type II IFN does not
have any significant effect (around 1.3 fold increase).
Effect of IFNs on retroviral restriction in primate cells
We next examined whether the increase in TRIM5α or
TRIMCyp mRNA following type I IFN treatment can influ-
ence the cell permissivity to retroviral infections. For this
purpose, VSV-G-pseudotyped, GFP-encoding retroviral
vectors derived from HIV-1, N-MLV and NB-MLV were
prepared by transfection of 293T cells (see methods) and
titrated on MDTF cells. HeLa, CMMT, Vero or OMK cells
were stimulated with IFN-α, β or γ and challenged with
increasing doses of GFP-encoding retroviral vectors 24 h
later. MDTF cells were stimulated with universal type I IFN
and challenged with the same dose of virus. The percent-
age of transduced GFP-positive cells was determined by
FACS 48 h post-transduction. Figure 2 shows the results
obtained when MDTF, HeLa, CMMT and Vero cells were
challenged with either a small (MOI of 0.5 on MDTF cells)
or a large (MOI of 5 on MDTF cells) amount of virus.
In the absence of IFN treatment, N-MLV is restricted in
HeLa and Vero cells, whereas HIV-1 is blocked in CMMT
and Vero cells. As expected, NB-MLV infection is not
affected in any cell line. Furthermore, IFN-treatment of
MDTF cells, which are devoid of any restriction factor,
does not affect their capacity to be transduced by any ret-
roviral vector. We did not observe any dramatic effect on
retroviral restriction levels in IFN-treated primate cells at
this low multiplicity of infection. IFN-β was found to be
the most effective in enhancing TRIM5α-mediated restric-
tion, in accordance with the results of expression enhance-
ment. Following IFN-β treatment, we observed a low but
reproducible enhancement of N-MLV restriction in HeLa
and Vero cells, as well as a higher restriction towards HIV-
1 infection in CMMT cells. This moderate effect of IFN at
low MOI is probably due to the fact that the constitutive
amount of TRIM5α in the cells is sufficient to restrict a
small amount of virus, whereas at higher MOI, it can be
predicted that an increased expression of TRIM5α would
prevent its saturation by incoming viruses, thus enhanc-
ing restriction. Indeed, when a higher dose of virus was
used (MOI of 5 on MDTF cells), we observed a much
higher restriction efficiency of N-MLV in HeLa and Vero
cells treated with type I IFN (Figure 2). In contrast, no sig-
nificant increase of HIV-1 restriction can be observed in
Vero or CMMT cells.
Together, our observations confirm that type I IFN can
modulate retroviral restriction in diverse primate cells.
However, we did not observe a direct and systematic cor-
relation between the levels of up-regulation of TRIM5α
expression and the enhancement of restriction activity.
Indeed, the IFN-induced reduction of infectivity of
TRIM5α-sensitive viruses seems to be dependent of
diverse parameters, such as the multiplicity of infection
and the basal restriction activity of cells against a given
virus.
In OMK cells, treatment with type I IFN was found to have
a greater influence on retroviral permissivity compared to
other primate cell lines (Figure 3). IFN-β treatment, in
particular, induces a 3-fold decrease of HIV-1 infectivity at
low multiplicity of infection (MOI of 0.5), which rises to
26-fold at high MOI (MOI of 5). More surprisingly, stim-
ulation with type I IFN also led to a reduced susceptibility
of OMK cells to NB-MLV and N-MLV infection, although
TRIMCyp is known to be inefficient to restrict MLV
strains, since MLV CA proteins do not interact with CypA.
Indeed, we found that IFN-β induces a 3.9 (at high MOI)
to 5.6 (at low MOI) fold increase of restriction towards N-
MLV and a 5.5 (at high MOI) to 5.6 (at low MOI) fold
increase of anti-NB-MLV restriction activity in OMK cells
(Figure 3 and Table 1). In order to determine whether IFN
initiates a wide and unspecific antiviral response in OMK
cells, we tested two other viruses which are known to be
insensitive to TRIMCyp-mediated restriction, B-MLV and
SIVmac (Figure 3) [17,18,22]. Interestingly, B-MLV per-
missivity is also affected by IFN treatment, whereas OMK
cells remain fully permissive to SIVmac. The fact that SIV-
mac is unaffected by this IFN-induced block proves that
the loss of infectivity we observed with MLV is not the
consequence of an increased cell mortality due to IFN
treatment. Since IFN-β gave more contrasted results than
IFN-α, we decided to pursue our study with IFN-β only.
Table 1 summarizes the effect of IFN-β on retroviralRetrovirology 2008, 5:59 http://www.retrovirology.com/content/5/1/59
Page 6 of 15
(page number not for citation purposes)
Modulation of anti-retroviral activity in primate cells by IFNs Figure 2
Modulation of anti-retroviral activity in primate cells by IFNs. MDTF, HeLa, CMMT, Vero or OMK cells were stimu-
lated with universal type I IFN (U), IFN-α, β or γ or left untreated (-), and transduced 24 h later with VSV-pseudotyped GFP-
expressing N-MLV (N), HIV-1 (HIV) or NB-MLV (NB) at low (MOI = 0.5) or high (MOI = 5) multiplicity of infection (as deter-
mined on MDTF cells). The percentage of transduced (GFP-positive) cells was determined by FACS 48 h post-transduction.
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restriction in all tested primate cell lines. Results are
expressed as fold restriction, which represents the ratio of
untreated to IFN-treated cells to be transduced by the GFP-
encoding retroviral vectors. As shown, IFN-β significantly
increases (fold restriction > 2) the restriction of N-MLV in
HeLa and Vero cells, whereas it induces a wide-spectrum
anti-retroviral activity in OMK cells affecting HIV-1, NB-
MLV, N-MLV and B-MLV but not SIVmac.
Therefore, our observations suggest that OMK cells
express an IFN-inducible anti-retroviral protein other
than TRIMCyp, which can interfere specifically with cer-
tain retroviruses.
The IFN-induced anti-retroviral activity in HeLa and Vero 
cells is TRIM5α-dependent
In order to verify whether the increased restriction activity
towards N-MLV infection in HeLa and Vero cells was due
to the IFN-induced TRIM5α, cells were first transfected
with a siRNA targeting TRIM5α, treated with IFN-β 24 h
later, and finally challenged the next day with N-MLV at a
MOI of 5 (as determined on MDTF cells). Three siRNA
were used, which silence human (H1 and HA2) or African
green monkey (HA2 and A3) TRIM5α expression (Figure
4A). A siRNA targeting luciferase (Luc) was used as a con-
trol. As shown in Figure 4B, the IFN-induced enhance-
ment of N-MLV restriction in HeLa and Vero cells is
almost completely lost when TRIM5α expression is down-
regulated by either of the two siRNA, thus suggesting that
TRIM5α is the main mediator of the IFN-induced N-MLV
restriction. In contrast, no effect on B- or NB-MLV infectiv-
ity can be observed following TRIM5α silencing in HeLa
or Vero cells, as expected (not shown).
The IFN-induced anti-MLV activity in OMK cells is 
TRIMCyp-independent
We used the same strategy in order to confirm the exist-
ence of an IFN-induced TRIMCyp-independent retroviral
restriction activity in OMK cells. For this purpose, we used
a siRNA targeting CypA as well as the CypA C-terminal
portion of TRIMCyp. The anti-Luc siRNA was used as con-
trol. Figure 5A shows the quantification of TRIMCyp
expression in siRNA-transfected OMK cells by quantita-
tive RT-PCR. As expected, OMK cells transfected with the
TRIMCyp siRNA lost their capacity to restrict HIV-1, as
compared to cells transfected with the Luc siRNA (Figure
5B). Next, we tested the effect of TRIMCyp silencing on
retroviral restriction following IFN-β stimulation. One
day after siRNA transfection, OMK cells were stimulated
with 1000 U/ml of IFN-β and challenged with one of the
four retroviruses found to be restricted: N-MLV, B-MLV,
NB-MLV or HIV-1. All retroviral vectors were used at the
same titer, corresponding to the viral dose that gives a
MOI of 5 on MDTF cells. As shown in Figure 5C, the IFN-
β-induced restriction of N-, B- and NB-MLV is not affected
by TRIMCyp silencing, thus demonstrating that another
mediator is involved in this anti-retroviral activity. In the
case of HIV-1, the extinction of TRIMCyp expression pre-
vents the IFN-induced enhancement of viral restriction,
confirming the fact that TRIMCyp is the main mediator of
the IFN-induced anti-HIV-1 activity in OMK cells.
To further address the question of the involvement of
TRIMCyp in the IFN-induced anti-retroviral activities, we
examined the effect of IFN-β stimulation on retroviral
transduction in the presence of CsA, which is known to
relieve the TRIMCyp-mediated restriction in OMK cells
[14,15,21,22]. OMK cells were stimulated with 1000 U/
ml of IFN-β and challenged with retroviral vectors 24 h
later in the presence of CsA. We found that IFN-induced
restriction of HIV-1 was partially relieved by CsA, thus
confirming that TRIMCyp is the main mediator of the
IFN-induced anti-HIV restriction in OMK cells (Figure
6A). In contrast, CsA treatment had no effect on the IFN-
induced activity against N-, B- and NB-MLV, thus confirm-
ing that TRIMCyp is not responsible for the IFN-induced
block of MLV infection.
This was further confirmed by comparing the restriction
profile of HIV-1, SIVmac and HIV-1 containing the CA
protein of SIVmac (HIV SCA) following IFN-β stimulation
of OMK cells. As shown in Figure 6B, the HIV SCA chi-
mera virus is as insensitive to IFN-β treatment as SIVmac,
compared to HIV-1.
The IFN-induced block in OMK cells targets an early step 
of MLV replication
Since IFNs can induce several antiviral mediators acting at
different stages of viral replication, we next examined
Table 1: Effect of IFN-β treatment on retroviral restriction.
FOLD RESTRICTION
HIV-1 N-MLV NB-MLV B-MLV SIVmac
MOI 0.5 5 0.5 5 0.5 5 0.5 5 0.5 5
MDTF 1.2 1.0 1.0 1.1 1.1 1.0 1.1 1.1 1.1 1.0
HeLa 1.5 1.1 3.7 7.6 1.9 1.4 nt nt nt nt
CMMT 2.8 1.2 1.1 1.0 1.1 1.1 nt nt nt nt
Vero 1.2 1.3 4.4 8.8 1.5 1.2 nt nt nt nt
OMK 2.9 26.1 5.6 3.9 5.6 5.5 2.1 3.9 1.1 1.1
HeLa, CMMT, Vero or OMK cells were stimulated with IFN-β and 
transduced 24 h later at a MOI of 0.5 or 5 (as determined on MDTF 
cells) with HIV-1, N-MLV, NB-MLV, B-MLV or SIVmac, as indicated. 
The same experiment was performed in parallel on MDTF cells 
treated or not with universal type I IFN. Fold restriction represents 
the ratio of untreated to IFN-treated cells to be transduced by the 
GFP-encoding retroviral vectors. A significant enhancement of 
retroviral restriction is defined as a ratio > 2 (in bold). Data are from 
a typical experiment representative of three independent 
experiments. nt: not tested.Retrovirology 2008, 5:59 http://www.retrovirology.com/content/5/1/59
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which step of the viral cycle is inhibited in response to IFN
treatment of OMK cells.
First, we challenged naive or IFN-β-treated OMK cells with
SIVmac, NB-MLV, B-MLV, HIV-1 or N-MLV and extracted
total DNA 6 h post-transduction. Reverse transcripts were
detected in cell extracts by PCR using GFP primers. In
accord with the mode of action of TRIMCyp, we observed
an inhibition of viral DNA synthesis in the case of HIV-1
infection, which is even more pronounced when cells are
pretreated with IFN-β (Figure 7). In contrast, the amount
of SIVmac reverse transcripts is comparable between naive
and IFN-stimulated cells, as expected. Interestingly, the
amount of reverse transcripts significantly decreases in
cells treated with IFN-β following infection with NB-, B-
or N-tropic MLV strains. We concluded from this experi-
ment that IFN-β treatment interferes with an early step of
the MLV replication cycle, prior to or during reverse tran-
scription.
Discussion
In this study, we have shown that type I (α and β) IFN
increases TRIM5α expression in human, African green
monkey and rhesus macaque cell lines, as well as TRIM-
Cyp expression in owl monkey cells. A previous study
reported that human TRIM5α expression can be directly
up-regulated by IFN-β through a putative interferon-stim-
ulated response element (ISRE) within its promoter [25].
Our data are in agreement with the results published by
Asaoka et al. [25], as we observed in HeLa cells an 8- to 9-
IFN-induced anti-retroviral activities in primate cells Figure 3
IFN-induced anti-retroviral activities in primate cells. OMK cells were treated with human IFN-α, β or γ and trans-
duced 24 h later with VSV-pseudotyped GFP-expressing N-MLV (N), HIV-1 (HIV), NB-MLV (NB), B-MLV (B) or SIVmac (SIV) 
at low (MOI = 0.5) or high (MOI = 5) multiplicity of infection. The percentage of transduced cells was determined by FACS 48 
h post-transduction.Retrovirology 2008, 5:59 http://www.retrovirology.com/content/5/1/59
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TRIM5α is the main mediator of the IFN-induced N-MLV restriction Figure 4
TRIM5α is the main mediator of the IFN-induced N-MLV restriction. A. HeLa and Vero cells were transfected with a 
siRNA targeting luciferase (Luc) or TRIM5α (siRNA H1, HA2 or A3), as indicated, and stimulated 24 h later with 1000 U/ml of 
IFN-β for 8 h. Total RNA was extracted and the levels of TRIM5α mRNA were determined by quantitative RT-PCR and nor-
malized to GAPDH. The mean ± SD of duplicates is shown. B. HeLa or Vero cells were transfected with siRNA targeting luci-
ferase (Luc), TRIM5αhu (H1 or HA2) or TRIM5αagm (HA2 or A3), as indicated. The next day, cells were stimulated with 1000 
U/ml of IFN-β for 8 h and challenged with a GFP-expressing N-MLV vector. The percentage of GFP-positive cells was deter-
mined by FACS 48 h post-transduction. Data are from a typical experiment representative of three independent experiments.
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The IFN-induced MLV restriction activity in OMK cells is independent of TRIMCyp Figure 5
The IFN-induced MLV restriction activity in OMK cells is independent of TRIMCyp. A. OMK cells were transfected 
with a siRNA targeting luciferase (Luc) or TRIMCyp (as well as CypA), as indicated, and stimulated 24 h later with 1000 U/ml 
of IFN-β for 8 h. Total RNA was extracted and the levels of TRIMCyp mRNA were determined by quantitative RT-PCR and 
normalized to GAPDH. The mean ± SD of duplicates is shown. B. OMK cells were transfected with anti-Luc (diamonds) or 
anti-TRIMCyp (triangles) siRNA and transduced 48 h later with increasing doses of HIV-1. The percentage of GFP-positive cells 
was determined by FACS 48 h post-transduction. C. Same experiment as in panel B, except that cells were challenged with 
HIV-1, N-MLV, B-MLV or NB-MLV (at a MOI of 5), following siRNA and IFN-β treatments. The percentage of GFP-positive 
cells was determined by FACS 48 h post-transduction. Data are from a typical experiment representative of three independent 
experiments.
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The IFN-induced enhancement of anti-HIV-1 restriction in OMK cells is due to TRIMCyp Figure 6
The IFN-induced enhancement of anti-HIV-1 restriction in OMK cells is due to TRIMCyp. A. OMK cells were 
induced with IFN-β and challenged 24 h later with GFP-expressing HIV-1, N-MLV, B-MLV or NB-MLV at a MOI of 5. CsA (5 
μM) was added 2 h before transduction. Percentage of transduced cells was determined by FACS 48 h post-transduction. Fold 
restriction represents the ratio of untreated to IFN-β-treated cells to be transduced by the GFP-encoding retroviral vectors. 
Results are representative of two independent experiments with comparable results. A significant enhancement of retroviral 
restriction is defined as a ratio > 2. B. OMK cells were stimulated with IFN-β and transduced 24 h later with VSV-pseudotyped 
GFP-expressing HIV-1, SIVmac or HIV-1 SCA vectors at a MOI of 1. The percentage of transduced cells was determined by 
FACS 48 h post-transduction. Fold restriction represents the ratio of untreated/IFN-β-treated cells to be transduced. As in 
panel A, a significant enhancement of retroviral restriction is defined as a ratio > 2.
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fold increase of TRIM5α expression with IFN-β and no
effect with IFN-γ. In contrast, we found that IFN-α was
almost as efficient as IFN-β in stimulating human TRIM5α
expression, in agreement with another recent study [31].
It should be noted that the TRIM5α expression increase in
CMMT cells is not as strong as in the other primate cells,
with a 3- to 3.5-fold increase following stimulation by
IFN-α or IFN-β, respectively.
We found that this type I IFN enhancement of TRIM5α
expression can influence cell permissivity towards retrovi-
ral infections in diverse primate cells. In most cases, we
observed a greater effect of IFN stimulation when high
concentrations of virus were used. This probably reflects
the fact that the constitutive amount of TRIM5α is suffi-
cient to block a small number of incoming viruses,
whereas at high MOI, an enhancement of TRIM5α intrac-
ellular concentration following IFN treatment facilitates
restriction by preventing TRIM5α saturation.
In human cells, IFN-β treatment increases TRIM5α expres-
sion by approximately 9-fold, and leads to a 7- to 8-fold
reduction of N-MLV permissivity. In contrast, IFN treat-
ment does not affect the permissivity of TRIM5αhu-insen-
sitive viruses, such as NB-MLV or HIV-1. These first
observations confirm a previous report showing that IFN-
α treatment of human cells both increases the level of
TRIM5α mRNA and potentates N-MLV restriction by
approximately 5-fold [31].
In the case of CMMT and Vero cells, TRIM5α expression is
also up-regulated following type I IFN treatment, but in
these cases, the increase of expression does not strictly cor-
relate with a decreased infectivity of TRIM5α-sensitive
viruses.
In rhesus macaque cells, at low MOI, we only observed a
moderate decrease of HIV-1 infectivity (2- to 3-fold reduc-
tion), in agreement with Sakuma et al. [31]. In contrast,
no effect on N-MLV infection can be observed. Surpris-
ingly, when a higher MOI was used, IFN-treated CMMT
cells showed no difference of susceptibility to either N-
MLV or HIV-1 infection, compared to untreated cells. This
relative insensitivity of CMMT to IFN treatment probably
reflects the fact that these cells constitutively express high
amount of TRIM5α (Figure 1B) compared to the other pri-
mate cell lines. Furthermore, this high constitutive expres-
sion is conjugated to a moderate enhancement of TRIM5α
expression in response to IFN (Figure 1D).
In Vero cells, we detected no effect of type I or type II IFNs
at low MOI, whereas at high MOI, we observed an
enhancement of N-MLV restriction following induction
by type I IFN only. Unlike N-MLV, HIV-1 infectivity was
not found to be significantly affected by the IFN-induced
up-regulation of TRIM5α expression. We believe that this
apparent discrepancy may be explained by the basal
restriction phenotype in Vero cells. Indeed, at constitutive
levels of TRIM5α expression, Vero cells restrict N-MLV
infection much more efficiently than HIV-1, suggesting
that their TRIM5α proteins recognize N-MLV CA better
than HIV-1 CA. Our observations suggest that IFN stimu-
lation can potentate restriction towards highly sensitive
viruses, but is not sufficient to enhance the restriction
activity towards less sensitive ones.
Importantly, we were able to demonstrate that the IFN-
induced restriction increase towards N-MLV observed in
human and African green monkey cells was mainly due to
the enhancement of TRIM5α expression, demonstrating
that TRIM5α is the main mediator of the anti-retroviral
activity of type I IFN in these cells.
Several studies have demonstrated that IFN-α can inter-
fere with early and late steps of HIV-1 replication, in vitro
[32-35]. Although we have only tested the effect of IFN on
HeLa cells rather than primary blood cells, our results are
not in favor of a direct implication of TRIM5α in the early
anti-HIV-1 block induced by IFN in human cells. Indeed,
up-regulation of TRIM5α expression by type I IFN was not
found to correlate with a significant decrease in HIV-1 per-
missivity. In this context, APOBEC3G, another cellular
The IFN-induced block occurs early in the MLV replication  cycle Figure 7
The IFN-induced block occurs early in the MLV repli-
cation cycle. OMK cells were treated or not with 1000 U/
ml of IFN-β and challenged 24 h later with DNase-treated 
GFP-expressing SIVmac (SIV), HIV-1 (HIV), N-, B-, or NB-
tropic MLV vectors. The same experiment was performed in 
parallel in the presence of AZT at 5 μM during infections. 
Total DNA was extracted 6 h post-transduction and the 
amount of reverse transcripts was estimated by PCR using 
GFP primers. A PCR on CypA was also performed as a con-
trol.Retrovirology 2008, 5:59 http://www.retrovirology.com/content/5/1/59
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IFN-induced anti-retroviral factor, is more likely to play a
role as a mediator of the early IFN-α-mediated anti-HIV
block in human cells [36], whereas the possible involve-
ment of TRIM5α in the late steps remains to be addressed
[31].
The second part of our study focused on the characteriza-
tion of IFN-induced modulation of retroviral infection
susceptibility in owl monkey cells. Cells derived from this
New World monkey species express a TRIMCyp fusion
protein which allows them to specifically interfere with
viruses whose capsid can bind CypA, such as HIV-1, FIV
and SIVagm [18,22]. In contrast, MLV and SIVmac capsid
proteins do not bind CypA and these viruses are in conse-
quence insensitive to TRIMCyp restriction.
First, we observed a 3 (at a MOI of 0.5) to 26-fold (at a
MOI of 5) reduction of HIV-1 permissivity following stim-
ulation of OMK cells with type I IFN, which can be attrib-
uted almost entirely to the IFN-induced up-regulation of
TRIMCyp expression.
Surprisingly, in addition to this strong enhancement of
HIV-1 restriction following type I IFN stimulation of OMK
cells, we also observed a significant and reproducible
restriction of MLV. This MLV block is independent of the
strain tropism, since N-, B- and NB-tropic MLV strains
were found to be sensitive. Many mammalian cells are
able to restrict MLV, but in all cases, the block only affects
N-tropic strains [37], with the exception of murine NIH-
3T3 cells which express a B-tropic MLV-specific restriction
factor, known as Fv1n (reviewed in [38,39]). We were able
to demonstrate that this IFN-induced anti-MLV activity is
independent of TRIMCyp expression and occurs early dur-
ing the MLV replication cycle, before or during the reverse
transcription step. In contrast to MLV, we found that SIV-
mac was not affected by IFN-treatment in OMK cells. Even
though the effect of IFN-treatment in OMK cells has never
been investigated, this observation was unexpected.
Indeed, in human cells, IFN-treatment was found to block
an early step of SIVmac replication, between viral entry
and reverse transcription [40,41]. Furthermore, IFNs are
known to activate multiple antiviral proteins which
induce a wide-spectrum antiviral response. Thus, our
results suggest the absence of IFN-induced antiviral
response against SIVmac in OMK cells.
Our main results on the effect of IFNs on TRIM5α or
TRIMCyp expression and on retroviral restriction in pri-
mate cells are summarized in a heat-map representation
(Figure 8).
Several cellular proteins have been identified as mediators
of the antiviral activity of IFNs, such as Protein Kinase
RNA-dependent, 2'5' oligoadenylate synthetase/RNase L,
and certain Mx proteins (reviewed in [42]). Interestingly,
in addition to these well characterized IFN-induced anti-
viral mediators, some other proteins belonging to the
TRIM protein family have also been involved in IFN-
induced antiviral defense, such as TRIM5α [25,31], PML/
TRIM19 (for review, see [43,44]), TRIM22 [45,46] or
TRIM25 [47]. These observations suggest that the entire
TRIM family may constitute a family of antiviral factors
implicated in the IFN-induced intracellular innate immu-
nity [9]. In this respect, a systematic study of the expres-
sion of mouse TRIM genes in immune cells in response to
various stimuli, including IFN treatment and viral infec-
tion, provides new insights into the implication of the
TRIM family in antiviral defense[48]. The number of
TRIM proteins up-regulated by IFN and/or implicated in
antiviral resistance raises the possibility of the involve-
ment of a TRIM protein other than TRIMCyp in the IFN-
induced anti-MLV restriction we observed in OMK cells.
Apart from TRIMCyp, the only TRIM protein that has been
Effects of IFNs on TRIM5 expression and retroviral restriction in primate cells Figure 8
Effects of IFNs on TRIM5 expression and retroviral restriction in primate cells. Left: Effect of IFNs on TRIM5α 
(HeLa, CMMT and Vero) and TRIMCyp (OMK) mRNA expression, expressed as fold increase (IFN-treated/untreated cells). 
Right: Effect of IFN-β treatment on retroviral restriction, expressed as fold restriction (untreated/IFN-treated cells).
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characterized so far in OMK cells is TRIM1 [8]. However,
since it was found to interfere specifically with N- but not
B-tropic strains of MLV, this protein is unlikely to play a
role in the observed phenotype. Whether it belongs to the
TRIM protein family or not, the identification of the medi-
ator(s) of the IFN-induced anti-MLV restriction in owl
monkey cells will need further investigation.
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